Mammary Gland: Focus on metabolic health
https://doi.org/10.14341/brh12767
Abstract
This review considers current ideas about the stages of development of pathological dysplastic processes in the mammary glands, data from reviews and meta-analyzes to study the causes of their development, factors of progression, the risk of their further influence on the formation of breast cancer. The use of a selective estrogen receptor modulator drug is considered as an etiopathogenetic correction of the patient’s existing disease, as its main pathological cause, and a risk factor for further proliferative and mitotic activity — long-term hyperestrogenism, the results of clinical studies in real clinical practice were evaluated.
About the Authors
A. F. Vesnina
Endocrinology Research Centre named after аcademician I.I. Dedov
Russian Federation
Russian Federation
Anna F. Vesnina, PhD
11 Dm. Ulyanova street, 117036 Moscow
E. N. Andreeva
Endocrinology Research Centre named after аcademician I.I. Dedov; Russian University of Medicine
Elena N. Andreeva, MD, PhD, Professor
Moscow
Zh. A. Uzhegova
Endocrinology Research Centre named after аcademician I.I. Dedov
Zhanna A. Uzhegova, MD, PhD
Moscow
References
1. Southey MC, Winship I, Nguyen-Dumont T. PALB2: research reaching to clinical outcomes for women with breast cancer. Hered Cancer Clin Pract. 2016;14(1):9. doi: https://doi.org/10.1186/s13053-016-0049-2
2. Kolak A, Kamińska M, Sygit K, et al. Primary and secondary prevention of breast cancer. Ann Agric Environ Med. 2017;24(4):549-553. doi: https://doi.org/10.26444/aaem/75943
3. Bodewes FTH, van Asselt AA, Dorrius MD, Greuter MJW, de Bock GH. Mammographic breast density and the risk of breast cancer: A systematic review and meta-analysis. Breast. 2022;66:62-68. doi: https://doi.org/10.1016/j.breast.2022.09.007
4. Ghosh K, Vierkant RA, Frank RD, Winham S, Visscher DW, et al. Association between mammographic breast density and histologic features of benign breast disease. Breast Cancer Res. 2017;19(1):134
5. Reeves GK, Pirie K, Beral V, Green J, Spencer E, Bull D. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ. 2007;335(7630):1134. doi: https://doi.org/10.1136/bmj.39367.495995.AE
6. Raglan O, Kalliala I, Markozannes G, Cividini S, Gunter MJ, et al. Risk factors for endometrial cancer: An umbrella review of the literature. Int J Cancer. 2019;145:1719–30
7. Zhao H, Yang H, Li Z, Ge Z, Zhou M, Li L, He J. Urine levels of estrogen and its metabolites in premenopausal middle-aged women with different degrees of obesity and their correlation with glucose and lipid metabolism. Heliyon. 2023;9(11):e22362
8. Baylyuk E. N. Clinicomorphologic features of proliferative processes in mammary gland of patients with uterine myoma/ E. N. Baylyuk // Journal of Obstetrics and Women’s diseases. Issue 1. — 2010. — T. LIX. — pp. 98-105.
9. Zhao C, Shang A, Wu H, Li Q, Peng L, Yue C. Causal relationship between genetically predicted uterine leiomyoma and cancer risk: a two-sample Mendelian randomization. Front Endocrinol (Lausanne). 2024 Aug 29;15:1429165. doi: https://doi.org/10.3389/fendo.2024.1429165
10. Ovsyannikova T.V., Abilities of therapy for dyshormonal mammary gland pathology in females with gynecological diseases / Obstetrics, gynecology and reproduction. — 2010. — Vol.4. — No. 2. — pp. 28-32
11. Collins LC, Aroner SA, Connolly JL, Colditz GA, Schnitt SJ, Tamimi RM. Breast cancer risk by extent and type of atypical hyperplasia: An update from the Nurses’ Health Studies. Cancer. 2016;122(4):515-20. doi: https://doi.org/10.1002/cncr.29775
12. Visscher DW, Frost MH, Hartmann LC, Frank RD, Vierkant RA, et al. Clinicopathologic features of breast cancers that develop in women with previous benign breast disease. Cancer. 2016;122(3):378-85. doi: https://doi.org/10.1002/cncr.29766
13. Ruan X, et al. The ratio of the estradiol metabolites 2-hydroxyestrone (2-OHE1) and 16α-hydroxyestrone (16-OHE1) may predict breast cancer risk in postmenopausal but not in premenopausal women: two case-control studies. Arch Gynecol Obstet. 2015;291(5)
14. Zhao H, Yang H, Li Z, Ge Z, Zhou M, Li L, He J. Urine levels of estrogen and its metabolites in premenopausal middle-aged women with different degrees of obesity and their correlation with glucose and lipid metabolism. Heliyon. 2023;9(11):e22362
15. Harvie M, et al. Randomised controlled trial of intermittent vs continuous energy restriction during chemotherapy for early breast cancer. Br J Cancer. 2022;126(8):1157-1167
16. Krasnopolskaya KV, Balan VE, Ershova IYu, Skorik EO, Malygin SE, Orazov MR, Toktar LR, Lagutina EV. Mastalgia in infertility: search for additional possibilities of therapy. Gynecology. 2021;23(4):354–363. doi: https://doi.org/10.26442/20795696.2021.4.201084
17. Smetnik V.P., Gavisova A.A., Bilak N.P., Drukh V.M. Indolecarbinol efficacy for mastalgia treatment. Russian Journal of Human Reproduction. 2013;(5):49-53.
18. Amarakoon D, Lee W-J, Tamia G, Lee S-H. Indole-3-Carbinol: Occurrence, Health-Beneficial Properties, and Cellular/Molecular Mechanisms. Annu Rev Food Sci Technol. 2023;14(1):347-366. doi: https://doi.org/10.1146/annurev-food-060721-025531
19. Vandeeva E.N., Protasova A.E., Raskin G.A., Yarmolinskaya M.I. Morphological features of benign mammary dysplasia in women with endometriosis-associated infertility // RMJ. Medical Review. 2018. № 10. P. 22–25.
20. Tagieva, Tarana Teymur kyzy. Fibrocystic breast disease in gynecologist’s practice: diagnosis, prognosis, management tactics: abstract of the dissertation... Doctor of Medical Sciences: 14.00.01 / Tagieva Tarana Teymur kyzy; [Place of protection: Scientific Center of Obstetrics, Gynecology and Perinatology of the Russian Academy of Medical Sciences. — Moscow, 2009. — 46 p.
21. Farland L V., Tamimi RM, Heather Eliassen A, et al. A prospective study of endometriosis and risk of benign breast disease. Breast Cancer Res Treat. 2016;159(3):545-552. doi: https://doi.org/10.1007/s10549-016-3957-y
22. Baylyuk, E. N. Clinical and morphological features of proliferative processes in the mammary gland in patients with uterine fibroids : dissertation... Candidate of Medical Sciences : 14.00.01 / Bailyuk Evgeny Nikolaevich; [Place of defense: State Institution «Scientific Research Institute of Obstetrics and Gynecology of the Russian Academy of Medical Sciences». - Saint Petersburg, 2008. - 117 p. : 31 ill.
23. Dyrstad SW, Yan Y, Fowler AM, Colditz GA. Breast cancer risk associated with benign breast disease: systematic review and meta-analysis. Breast Cancer Res Treat. 2015;149(3):569-575. doi: https://doi.org/10.1007/s10549-014-3254-6
24. Travis RC, Key TJ. Oestrogen exposure and breast cancer risk. Breast Cancer Res. 2003;5(5):239. doi: https://doi.org/10.1186/bcr628
25. Kit O.I, Franciync E.M., Bandovkina V.A., Shatova Y.S., Komarova E.F., Vereskunova M.I., Kuchkina L.P. Estrone’s metabolites content in the peripheral liquids and tissues among the patients with breast cancer of different ages and reproductive state. Fundamental research. №7, 2013
26. Amarakoon D, Lee W-J, Tamia G, Lee S-H. Indole-3-Carbinol: Occurrence, Health-Beneficial Properties, and Cellular/Molecular Mechanisms. Annu Rev Food Sci Technol. 2023;14(1):347-366. doi: https://doi.org/10.1146/annurev-food-060721-025531
27. Kiselev V.I., Smetnik V.P., Suturina L.V. Indolkarbinol (Indinol Forto) — a method of multitarget therapy with cyclic mastodynia. Obstetrics and gynecology. 2013;7:56–62.
28. Ashrafyan L, Rozhkova N, Prokopenko S, et al. The influence of indolcarbinol on cyclic mastalgia caused by benign breast dysplasia in routine clinical practice (research "APHRODITA"). Akushrstvo i Ginekologiya. 2024;2;134-142.doi: https://doi.org/10.18565/aig.2024.35
Supplementary files
Review
For citations:
Vesnina A.F., Andreeva E.N., Uzhegova Zh.A. Mammary Gland: Focus on metabolic health. Bulletin of Reproductive Health. 2025;4(2):37-47. (In Russ.) https://doi.org/10.14341/brh12767
Views:
24
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
